Exocrine Pancreatic Insufficiency Epidemiology Forecast Through 2034 Now Available

DelveInsight's "Exocrine Pancreatic Insufficiency (EPI) - Epidemiology Forecast - 2034" report delivers an in-depth understanding of Exocrine Pancreatic Insufficiency, historical and forecasted epidemiology, as well as the trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

To know in detail about the Exocrine Pancreatic Insufficiency epidemiology outlook, patient pool segmentation, disease burden, and forecasted trends, Click here: Exocrine Pancreatic Insufficiency Epidemiology Forecast https://www.delveinsight.com/report-store/exocrine-pancreatic-insufficiency-epidemiology-forecast-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr

Some of the Key Facts of the Exocrine Pancreatic Insufficiency Epidemiology Report:
• Across the 7MM, the highest prevalence of causative indications of EPI was observed in Type 2 Diabetes Mellitus, estimated at approximately 67,892,836 cases in 2017, with figures anticipated to rise through the forecast period (2020-2034).
• Acute Pancreatitis, Chronic Pancreatitis, Cystic Fibrosis, and Unresectable Pancreatic Cancer are identified as the foremost causative conditions driving the development of EPI across the 7MM.
• In Japan in 2017, the number of patients affected by key EPI causative conditions included approximately 61,961 cases of Acute Pancreatitis, 66,261 cases of Chronic Pancreatitis, 11,721 cases of Cystic Fibrosis, and 25,319 cases of Unresectable Pancreatic Cancer - all projected to increase through the forecast period.
• The incidence of EPI in chronic pancreatitis ranges from 30% in patients with mild disease to 85% in those with severe disease, underscoring the strong epidemiological link between pancreatic parenchymal damage and exocrine insufficiency.
• Approximately 85% of infants with cystic fibrosis have EPI at birth, highlighting the condition's significant presence in the pediatric rare disease population alongside its more common adult-onset presentations.
• EPI is most commonly caused by diseases that destroy the pancreatic parenchyma - including chronic pancreatitis, cystic fibrosis, and pancreatic resection - and is sometimes defined as enzyme output less than 10% of that necessary to sustain normal digestion.
• The EPI epidemiology report covers total prevalent cases, total diagnosed and treated cases, and prevalence of causative indications across the 7MM from 2017 to 2034.
• The Exocrine Pancreatic Insufficiency patient pool is expected to grow across the 7MM through 2034, driven by rising prevalence of Type 2 Diabetes Mellitus, chronic pancreatitis, and pancreatic cancer, combined with improving diagnostic recognition of EPI as a secondary consequence of these conditions.

Exocrine Pancreatic Insufficiency Overview
The pancreas is a dual-function organ with both exocrine and endocrine components critical for digestion, absorption, and nutrient metabolism. Normal digestion requires exocrine pancreatic function for macronutrient breakdown, primarily through enzymatic hydrolysis by lipase, amylase, and proteases including trypsin and chymotrypsin. Exocrine Pancreatic Insufficiency (EPI) refers to the maldigestion and malabsorption of nutrients resulting from a primary loss of functional parenchyma and/or impaired exocrine pancreatic function with insufficient enzyme activity.
The clinical presentation of EPI varies widely depending on the underlying cause, disease stage, diet, and other factors, complicating diagnosis and contributing to underrecognition. EPI most commonly arises as a consequence of chronic pancreatitis, cystic fibrosis, or pancreatic resection, though it can develop secondary to a range of other pancreatic and non-pancreatic conditions including Type 2 Diabetes Mellitus and pancreatic cancer.

Get a Free Sample for the Exocrine Pancreatic Insufficiency Epidemiology Report https://www.delveinsight.com/report-store/exocrine-pancreatic-insufficiency-epidemiology-forecast-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr

Exocrine Pancreatic Insufficiency Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends across the 7MM from 2017 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The section provides a detailed analysis of both the causative indication prevalence and the resulting EPI patient pool, enabling a comprehensive view of the disease burden.
Exocrine Pancreatic Insufficiency Epidemiology Segmentation:

The Exocrine Pancreatic Insufficiency Epidemiology report proffers epidemiological analysis for the study period 2017-2034 across the 7MM segmented into:
• Prevalence of Causative Indications of EPI (Chronic Pancreatitis, Acute Pancreatitis, Cystic Fibrosis, Unresectable Pancreatic Cancer, Type 2 Diabetes Mellitus)
• Total Prevalent Cases of Exocrine Pancreatic Insufficiency
• Total Diagnosed and Treated Cases of Exocrine Pancreatic Insufficiency

Download the report to understand which factors are driving Exocrine Pancreatic Insufficiency epidemiology trends @ EPI Epidemiology Forecast https://www.delveinsight.com/report-store/exocrine-pancreatic-insufficiency-epidemiology-forecast-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr

Exocrine Pancreatic Insufficiency Diagnosis and Disease Burden
Diagnosis of EPI is complicated by the absence of a consensus clinical definition, variable symptom presentation, and the fact that EPI frequently presents as a secondary condition overshadowed by its primary causative disease. While enzyme output below 10% of normal is sometimes used as a threshold, no universally accepted diagnostic standard exists. Common diagnostic approaches include fecal elastase testing, coefficient of fat absorption measurements, and imaging to assess pancreatic parenchymal damage.
The report assesses the disease risk and burden of Exocrine Pancreatic Insufficiency across the 7MM, quantifying patient share distribution and providing detailed growth opportunity insights by geography and causative indication. Epidemiology models are developed by Masters and PhD-level epidemiologists using transparent and consistent methodologies, supported by interactive dashboards showcasing disease trends across the full 11-year forecast period.

Explore detailed insights into market forecast, emerging therapies, market trends, and key players shaping the EPI landscape -Exocrine Pancreatic Insufficiency Market https://www.delveinsight.com/report-store/exocrine-pancreatic-insufficiency-epidemiology-forecast-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr

Exocrine Pancreatic Insufficiency Epidemiology Drivers
• Rising global prevalence of Type 2 Diabetes Mellitus - the single largest causative indication pool in the 7MM - expanding the EPI-at-risk population across all geographies
• Growing incidence of chronic pancreatitis, where EPI affects 30%-85% of patients depending on disease severity, driving a large and persistent secondary EPI burden
• Increasing survival rates among pancreatic cancer patients and improved post-surgical outcomes following pancreatic resection expanding the EPI-eligible patient population
• Greater clinical recognition of EPI as a secondary consequence of multiple primary pancreatic and metabolic conditions, improving diagnosis and treated case rates
• Expanding availability and adoption of fecal elastase testing and other non-invasive diagnostic tools supporting earlier EPI identification across the 7MM

Exocrine Pancreatic Insufficiency Epidemiology Barriers
• Absence of a universally accepted clinical definition of EPI creating inconsistency in diagnosis rates and treated case estimates across geographies
• High rate of EPI underdiagnosis driven by symptom overlap with other gastrointestinal conditions and the tendency for EPI to be overshadowed by its primary causative disease
• Variable access to specialist gastroenterology and pancreatic care in certain 7MM markets, limiting timely referral and diagnostic workup for EPI following primary disease confirmation

Scope of the Exocrine Pancreatic Insufficiency Epidemiology Report
• Study Period: 2017-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Epidemiology Segmentation: Prevalence of causative indications (Type 2 DM, chronic pancreatitis, acute pancreatitis, cystic fibrosis, unresectable pancreatic cancer), total prevalent cases, and total diagnosed and treated cases of EPI
• Disease Risk and Burden Assessment across all 7MM geographies
• 11-Year Forecast of Exocrine Pancreatic Insufficiency patient pool through 2034
• Key Questions Addressed: Historical and forecasted patient pool, CAGR of patient population growth, country-level highest prevalent population, causative indication distribution, and growth opportunities by geography

Company Name: DelveInsight Business Research LLP
Contact Person: Mehul Malhotra
Email: mmalhotra@delveinsight.com
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefit market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.